I think AMRN's future is dependent on ramping up sales around the world as fast as possible. KM said as much when he spoke recently at that financial thing. Once sales worldwide are a half billion dollars, anything from U.S. sales will just be gravy. All Amarin needed was for U.S. sales to hold up long enough to launch in Europe and elsewhere. We're almost there. Looking at last quarter's earnings report, I think KM, to his credit, has tamed the beast. In another six months, Wall Street will wake up to this fact too.
The Health Net settlement is a great thing, clearing the path to appeal the Hikma end of the ruling. And it lets the company wave the deal in the face of any insurance companies who treat the company unfairly. But Amarin's future doesn't depend on Health Net. And Denner, for all the adoring fans he has on this board, won't really be a factor either.
Market Data 
Markets 
AI
